drugset / Trial / NCT06877247

A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism

NCT06877247

Phase 1 Completed 5 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of \[14C\] SHR6508.

Timeline

Start
2024-12-23
Primary completion
2025-04-04
Completion
2025-10-11

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR6508 Unknown